Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis

Blood. 2011 Jan 6;117(1):246-9. doi: 10.1182/blood-2010-07-294447. Epub 2010 Oct 13.

Abstract

Transforming growth factor-β1 (TGF-β1) is the most important cytokine involved in the promotion of myelofibrosis. Mechanisms leading to its local activation in the bone marrow environment remain unclear. As a recent study has highlighted the role of thrombospondin-1 (TSP-1) in platelet-derived TGF-β1 activation, we investigated the role of TSP-1 in the TPO(high) murine model of myelofibrosis. Two groups of engrafted mice, WT TPO(high) and Tsp-1-null TPO(high), were constituted. All mice developed a similar myeloproliferative syndrome and an increase in total TGF-β1 levels in the plasma and in extracellular fluids of marrow and spleen. Surprisingly, we were able to detect the active form of TGF-β1 in Tsp-1-null TPO(high) mice. Accordingly, these mice developed marrow and spleen fibrosis, with intriguingly a higher grade than in WT TPO(high) mice. Our results show that TSP-1 is not the major activator of TGF-β1 in TPO-induced myelofibrosis, suggesting the contribution of another mechanism in the megakaryocyte/platelet compartment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Platelets / metabolism
  • Blood Platelets / pathology
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Female
  • Male
  • Megakaryocytes / metabolism
  • Megakaryocytes / pathology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Primary Myelofibrosis / chemically induced*
  • Primary Myelofibrosis / metabolism
  • Primary Myelofibrosis / pathology*
  • Spleen / metabolism
  • Spleen / pathology
  • Thrombopoietin / adverse effects*
  • Thrombospondin 1 / physiology*
  • Transforming Growth Factor beta1 / metabolism*

Substances

  • Thrombospondin 1
  • Transforming Growth Factor beta1
  • Thrombopoietin